At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 204 enrolled
Drug / intervention
ceftazidime/NXL104 + metronidazole +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Multicenter, Double-blind, Randomized, Comparative Study to Estimate the Safety, Tolerability and Efficacy of NXL104/Ceftazidime Plus Metronidazole vs. Meropenem in the Treatment of Complicated Intra-abdominal Infections in Hospitalized Adults
In Brief
A Phase 2 clinical trial evaluating ceftazidime/NXL104 + metronidazole and meropenem for Complicated Intra-abdominal Infections. Completed, enrolled 204 participants across 45 sites in 8 countries.
Detailed Summary
The purpose of this study is to determine whether NXL104 plus ceftazidime is effective in the treatment of complicated intra-abdominal infections as compared to a comparator group.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsComplicated Intra-abdominal Infections
CountriesBulgaria, France, India, Lebanon, Poland, Romania, Russia, United States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 2008
Enrollment StartMar 2009
Primary CompletionNov 2009
Study CompletionDec 2009
TodayJul 2026
First PostedSep 15, 2008
Enrollment StartMar 31, 2009
Primary CompletionNov 30, 2009
Study CompletionDec 31, 2009
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 17.8 years ago
Interventions
ceftazidime/NXL104 + metronidazoledrug
IV TID
meropenemdrug
IV TID